Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR)

被引：0
|
作者：
Ball, D. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Radiat Oncol, Melbourne, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Stereotactic ablative radiotherapy; contraindications;
D O I：
10.1016/j.jtho.2018.08.080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MTE24.02
引用
收藏
页码：S225 / S226
页数：2
相关论文
共 50 条
  • [21] Experience of lung stereotactic ablative body radiotherapy (SABR) in a non-academic cancer centre in the UK
    Iqbal, M. Shahid
    Cyriac, A.
    Aynsley, E.
    Shakespeare, D.
    Richmond, N.
    Walker, C.
    Piling, K.
    Peedell, C.
    LUNG CANCER, 2015, 87 : S46 - S47
  • [22] Recommendations for dose calculations of lung cancer treatment plans treated with stereotactic ablative body radiotherapy (SABR)
    Devpura, S.
    Siddiqui, M. S.
    Chen, D.
    Liu, D.
    Li, H.
    Kumar, S.
    Gordon, J.
    Ajlouni, M.
    Movsas, B.
    Chetty, I. J.
    XVII INTERNATIONAL CONFERENCE ON THE USE OF COMPUTERS IN RADIATION THERAPY (ICCR 2013), 2014, 489
  • [23] Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia
    Ghandourh, Wsam
    Holloway, Lois
    Batumalai, Vikneswary
    Chlap, Phillip
    Field, Matthew
    Jacob, Susannah
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 34 : 7 - 14
  • [24] CyberKnife stereotactic ablative radiotherapy (SABR) in patients with non-small cell lung cancer ( NSCLC)
    Leschenko, Y.
    Chebotareva, T.
    Spizhenko, N.
    Fedusenko, A.
    Sharaevskiy, O.
    Buryk, V.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S39 - S39
  • [25] Evaluating dose coverage and conformity in stereotactic ablative body radiotherapy (SABR) plans
    O'Keeffe, Serena
    Fleming, Cathy
    Vintro, Luis Leon
    Mcclean, Brendan
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2024, 118
  • [26] Stereotactic ablative body radiotherapy (SABR) for NSCLC oligometastatic patients: feasibility and outcomes
    Campisi, M. C.
    Navarria, P.
    Ascolese, A. M.
    De Rose, F.
    Alloisio, M.
    Infante, M.
    Palumbo, V.
    Reggiori, G.
    Tomatis, S.
    Scorsetti, M.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S119 - S119
  • [27] Implementation of Stereotactic Ablative Body Radiotherapy (SABR) for Spinal Oligometatases: Initial Experiences
    Smyth, M.
    Williams, M.
    Jones, S.
    Woodley, O.
    Bryant, A.
    Matthams, C.
    Maloney, H.
    Millin, T.
    Palaniappan, N.
    Rackley, T.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E57 - E57
  • [28] Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases
    Siva, S.
    Bressel, M.
    Loi, S.
    Sandhu, S.
    Tran, B.
    Mooi, J.
    Lewin, J.
    Azad, A.
    Colyer, D.
    Shaw, M.
    Chander, S.
    Cuff, K.
    Wood, S.
    Lawrentschuk, N.
    Murphy, D.
    Pryor, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S248 - S248
  • [29] Efficacy and safety profile of Stereotactic Ablative Radiotherapy (SABR) for multiple lung primaries
    Littlejohns, A.
    Janjua, T.
    Murray, P.
    Jain, P.
    Clarke, K.
    Dickinson, P.
    Teo, M.
    Saha, A.
    Franks, K.
    Sun, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S542 - S542
  • [30] Clinical implementation of stereotactic ablative radiotherapy (SABR) for lung early stage NSCLC
    Routsis, D.
    Dean, J.
    Archer, S.
    Ferriera, C.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S304 - S304
12345